{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-192735","form_type":"8-K","ticker":"STOK","cik":"0001623526","company_name":"Stoke Therapeutics, Inc.","filed_at":"2023-07-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.596333+00:00","generated_at":"2026-06-13T03:09:34.166464+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"STK-001 70mg achieves 80% median convulsive seizure reduction at 3 months in Dravet syndrome","bullets":["70mg multiple-dose cohort (n=6): median convulsive seizure reduction 80% at 3 months, 89% at 6 months after last dose.","30mg and 45mg OLE data show durable seizure reductions and improvements in cognition/behavior per VABS-III and BRIEF-P.","Safety: generally well-tolerated in 74 patients; one SUSAR attributed to drug; no treatment-related discontinuations.","Additional Phase 1/2a end-of-study data and Phase 3 planning update expected in Q1 2024 and H1 2024 respectively."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-192735","json":"https://secwatch.observer/filing/0001193125-23-192735.json","markdown":"https://secwatch.observer/filing/0001193125-23-192735.md","text":"https://secwatch.observer/filing/0001193125-23-192735.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1623526/000119312523192735/0001193125-23-192735-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1623526/000119312523192735/d530062d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T03:09:34.166464+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}